Aberrant AKT activation drives well-differentiated liposarcoma
Name
Gutierrez-2011-Aberrant AKT activat.pdf
Size
1.41 MB
Format
Adobe PDF
Checksum (MD5)
e6a07c82ed783d237f9896e082fc4b11
Author(s)
Gutierrez, Alejandro
Snyder, Eric
Marino-Enriquez, Adrian
Zhang, Yi-Xiang
Sioletic, Stefano
Kozakewich, Elena
Grebliunaite, Ruta
Ou, Wen-bin
Sicinska, Ewa
Raut, Chandrajit P.
Date Issued
September 2011
Journal
Proceedings of the National Academy of Sciences
Publisher
Proceedings of the National Academy of Sciences (PNAS)
Citation
Gutierrez, A. et al. “Aberrant AKT Activation Drives Well-differentiated Liposarcoma.” Proceedings of the National Academy of Sciences 108.39 (2011): 16386–16391. Web. 13 Apr. 2012.
Version
Final published version
Abstract
Well-differentiated liposarcoma (WDLPS), one of the most common human sarcomas, is poorly responsive to radiation and chemotherapy, and the lack of animal models suitable for experimental analysis has seriously impeded functional investigation of its pathobiology and development of effective targeted therapies. Here, we show that zebrafish expressing constitutively active Akt2 in mesenchymal progenitors develop WDLPS that closely resembles the human disease. Tumor incidence rates were 8% in p53 wild-type zebrafish, 6% in p53 heterozygotes, and 29% in p53-homozygous mutant zebrafish (P = 0.013), indicating that aberrant Akt activation collaborates with p53 mutation in WDLPS pathogenesis. Analysis of primary clinical specimens of WDLPS, and of the closely related dedifferentiated liposarcoma (DDLPS) subtype, revealed immunohistochemical evidence of AKT activation in 27% of cases. Western blot analysis of a panel of cell lines derived from patients with WDLPS or DDLPS revealed robust AKT phosphorylation in all cell lines examined, even when these cells were cultured in serum-free media. Moreover, BEZ235, a small molecule inhibitor of PI3K and mammalian target of rapamycin that effectively inhibits AKT activation in these cells, impaired viability at nanomolar concentrations. Our findings are unique in providing an animal model to decipher the molecular pathogenesis of WDLPS, and implicate AKT as a previously unexplored therapeutic target in this chemoresistant sarcoma.
Description
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1106127108/-/DCSupplemental.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1106127108
